Research on heart failure and its treatment. Covers light exposure, heart-in-a-dish models, microRNA therapy, and surgical interventions.
A phase 1 clinical trial of cardiac stem cells has shown promising results in patients with severe heart failure after a heart attack. LVEF increased from 30.3% to 38.5% at 4 months, and further improvement was seen at 1 year.
Researchers found that increased wave reflections are predictive of cardiovascular events and congestive heart failure, even with small increases in magnitude. This measure surpassed established risk factors like hypertension in predicting heart failure risk.
Research found that heart failure patients with low vitamin C intake had shorter intervals without major cardiac issues or death and were more likely to die from cardiovascular disease. Inflammation pathways in heart failure may contribute to poor health outcomes.
Scientists studying drugs for dementia treatment also find promise in treating heart failure, driven by a common enzyme. Preliminary studies suggest that blocking this enzyme may help slow the progression of both conditions.
Researchers at the University of Leeds have discovered that leg muscle dysfunction is related to the severity of symptoms in heart failure patients. Daily activity in these patients can be limited by impaired leg muscles, not just a failing heart.
A new long-term study reveals that heart transplantation is a safe and effective therapy, with survival rates improving by over 20% since its introduction in 1980. The study found that younger patients have better outcomes, while age negatively impacts survival rates.
A growing number of Canadians are living with heart failure, with approximately half a million affected. Simple tests and strategies can help reduce costs and improve outcomes for these patients. A new clinical risk score can guide admission vs. discharge decisions, predicting mortality among HF patients who present to the ED.
The study found a significant decline in hospitalization rates for heart failure among Medicare patients, with black men experiencing the lowest rate of decline. The researchers estimated that over 229,000 hospitalizations for heart failure were avoided in 2008 due to this decline.
A Yale University study found a 29.5% decline in heart failure hospitalization rates from 1998 to 2008, resulting in an estimated 229,000 fewer hospitalizations. One-year mortality rates also declined slightly, with black men experiencing the lowest rate of decline.
A new study found that adjusting therapy to keep NT-proBNP levels below 1,000 pg/ml reduced hospitalizations for heart failure symptoms by half and lowered rates of arrhythmias, stroke, heart attack, and cardiac death. Patients reported better quality of life and greater improvement in heart structure and function.
A collaborative network of scientists, including UNC's Cam Patterson, has been awarded a $6 million grant to explore the biology of heart failure and find new therapies. The project aims to define the role of proteotoxicity in clinically relevant models of heart failure.
A randomized controlled clinical study demonstrated that RESPeRATE can significantly relieve symptoms of heart failure in elderly patients. After 4 weeks of twice daily treatment sessions, patients showed a reduction in the severity of CHF measured by NYHA classification and dyspnea.
Recent studies have shown that aldosterone antagonists reduce mortality and cardiovascular complications in patients with heart failure. The benefits of these drugs are clear, with a 24% reduction in cardiovascular death and a 42% reduction in hospitalization for heart failure.
Researchers at Johns Hopkins Medicine found that a widely used pacemaker for heart failure works by raising regulator of G-protein-signaling proteins in the heart. This helps restore balance between two proteins, allowing the heart muscle to respond to hormones like adrenaline more effectively.
Research found that engaging in one healthy lifestyle behavior can decrease heart failure risk, while each additional behavior further reduces the risk. Key findings include: regular physical activity and a diet rich in vegetables lowering risk by 21-33% and 26-27%, respectively.
Researchers at Mount Sinai School of Medicine have identified SUMO1 as a potential therapeutic target for treating and preventing the progression of heart failure. Gene therapy with SUMO1 improved cardiac function in human and pig hearts, suggesting its critical role in pathogenesis.
A German team has developed a new non-invasive method to identify heart failure using an electronic nose, which can detect the condition with 89% sensitivity and 88% specificity. The study screened over 250 patients and found that the method was effective in distinguishing between different stages of heart failure.
A study of 663 advanced heart failure patients found that echocardiographic response (left ventricular reverse remodeling) was a better predictor of long-term mortality than clinical response. Echocardiographic response was independently associated with superior survival, with patients showing good response having a lower risk of death.
The PERMIT-CARE trial demonstrates that MitraClip treatment improves NYHA functional class and reverse left ventricular remodeling in approximately 70% of patients. The study shows that FMR reduction with MitraClip is feasible, safe, and leads to substantial improvement in heart failure patients who do not respond to CRT.
A study found that diastolic dysfunction prevalence increased by 39.2% in 4 years, with worsening function associated with heart failure risk. Age was a key predictor of developing diastolic dysfunction and heart failure.
The first clinical studies of omecamtiv mecarbil suggest it could be a promising treatment for systolic heart failure, improving heart muscle contraction and pumping function. The drug has dose-dependent and concentration-dependent effects on cardiac function, increasing stroke volume, ejection fraction, and fractional shortening.
A new class of drugs called cardiac myosin activators targets the motor proteins in heart failure patients, prolonging contraction duration and improving blood pumped per stroke. Omecamtiv mercabil shows promise as a safe and effective treatment option with minimal increased energy expenditure.
A study analyzing results from multiple international clinical trials of beta-blocker drugs found significant differences in survival rates among patients treated in different regions. US patients showed a lower survival rate compared to patients outside the US, while other countries demonstrated more substantial reductions in mortality.
A cross-sectional study found that older patients with heart failure and low left ventricle function experience reduced verbal memory performance, particularly delayed recall and recognition. The association between heart failure severity and cognitive impairment is complex and warrants further research.
A recent study published in Cell Stem Cell found that low doses of erythropoietin (EPO) may reduce the risk of heart failure associated with some anticancer therapies. EPO was shown to bind to cardiac stem cells and restore their ability to form new blood vessels, preserving cardiac function.
Kansas State University researcher Michele Borgarelli has made significant strides in understanding chronic mitral valve disease in dogs, a condition similar to the same disease affecting humans. He aims to identify dogs at higher risk for progression of the disease to develop early interventions.
Research ties aging muscle weakness to leaky calcium channels in muscle cells. A drug already in Phase II clinical trials for heart failure may help repair these channels, restoring muscle function. The study's findings suggest a new approach to addressing age-related muscle wasting by focusing on muscle function rather than mass.
A Montreal Heart Institute study found that ivabradine significantly improves left ventricular diastolic dysfunction and reduces cardiac fibrosis in rabbits with cholesterol-enriched diets. The results suggest that ivabradine may be an effective treatment for patients with diastolic heart failure.
Researchers at Thomas Jefferson University have demonstrated the long-term therapeutic effectiveness and safety of S100A1 gene therapy in a large animal model of heart failure. The therapy works by restoring normal levels of the calcium-sensing protein, preventing and reversing cardiac dysfunction.
A study in JAMA found that stress cardiomyopathy (SC) affects postmenopausal women primarily, but also younger patients, men, and those without an identifiable stressful trigger. CMR imaging identified specific criteria for diagnosis, which showed complete normalization of LV function after follow-up imaging.
A study published in Journal of Cardiovascular Nursing found that heart failure patients who followed doctor's advice for self-care had lower levels of myocardial stress and systemic inflammation. This suggests that effective self-care behaviors can influence health outcomes through multiple cardioprotective means.
Researchers from Peninsula College of Medicine and Dentistry discovered a potential therapeutic strategy for managing heart failure by modulating the interaction between hydrogen sulphide (H2S) and nitric oxide. The study found that this 'cross talk' can have positive effects on heart health and may lead to new drug therapies.
Researchers at Mount Sinai School of Medicine developed a gene therapy called SERCA2a that stabilized or improved cardiac function in people with severe heart failure. Patients receiving the high-dose therapy experienced substantial clinical benefit and significantly reduced cardiovascular hospitalizations.
A study of 36,261 patients found that diastolic dysfunction was associated with a higher mortality rate, particularly in moderate and severe cases. The researchers suggest that early identification of advanced diastolic dysfunction may lead to earlier interventions and improved outcomes.
A US EPA study has found that peat wildfire smoke is associated with a significant increase in emergency room visits for respiratory and cardiovascular effects. The study discovered a 37% rise in ER visits for people experiencing symptoms of heart failure during a period of dense smoke exposure.
The European Society of Cardiology recommends redefining cardiac hypertrophy as myocardial remodelling to account for changes in non-myocyte cells and cell division. This change aims to improve communication among researchers and clinicians, leading to better risk stratification and treatment.
A study published in Panminerva Medica reveals that Pycnogenol and CoQ10 taken as an adjunct to medication strengthens the heart, improving blood volume output, physical fitness, blood pressure, and respiratory rate. The combination also showed significant improvements in patients' quality of life, including reduced symptoms and increa...
A new meta-analysis study found that three-lead cardiac pacemakers implanted in those with heart failure fail to help up to 40 percent of patients. Patients with less severe electrical disturbance in their hearts did not receive any benefit from these devices.
A new study reveals that patients implanted with the HeartMate II left ventricular assist device (LVAD) are at a higher risk of internal bleeding than those who received an earlier model. The research found nearly 22% of patients experienced gastrointestinal bleeding, while eight percent suffered from major adverse neurological events.
A national study found that optimally implementing key guideline-recommended therapies for all eligible heart failure patients could prevent up to 67,996 deaths annually. The study highlights the potential health benefits of more consistent use of evidence-based treatments.
A study published in Clinical Cardiology reveals that CRT significantly improves libido, erectile dysfunction, and sexual performance in men with chronic heart failure. The therapy improves functional capacity and ejection fraction, leading to better sexual health outcomes.
A study found that elderly patients with heart failure symptoms who have high levels of biomarkers copeptin and NT-proBNP in their blood have an increased risk of all-cause death. The combination of these biomarkers provides greater prognostic information, suggesting potential therapeutic targets for treatment.
A study found that postmenopausal women who ate more baked/broiled fish had a 30% lower risk of heart failure compared to those who rarely ate it. Darker fish, such as salmon and mackerel, were associated with a greater risk reduction than lighter fish.
Researchers at the Peter Munk Cardiac Centre have identified a protein called PINK1 as a potential trigger for heart failure. The absence of this protein causes heart cells to produce less energy, leading to cell death and hypertrophy.
Recent meta-analyses show telemedical monitoring can improve overall survival by 17-47% in CHF patients. Two trials presented at the Heart Failure Congress 2011 found benefits in specific subgroups, including those with prior decompensation and no depression.
Patients with mild to moderate dyssynchrony and preserved contractile function benefit most from CRT-D, according to the latest MADIT-CRT trial analysis. The study found that improvements in synchrony and contractile function are associated with reduced death and heart failure events.
A sub-analysis of the EMPHASIS-HF trial found eplerenone significantly reduced new onset atrial fibrillation and flutter in patients with class 2 heart failure. The benefits of eplerenone were similar in patients with and without atrial fibrillation at baseline.
A novel therapy that stimulates the nerve controlling diaphragm has been shown to improve breathing patterns, reduce blood oxygenation levels, and lower heart rate in patients with both heart failure and central sleep apnea. This treatment offers a promising alternative to existing therapies like CPAP for patients with heart failure.
Researchers found a relationship between discretionary heart failure admissions and higher readmission rates. Hospitalization after heart attack shows no correlation with readmission rates, contrary to expectations.
A six-month study found that younger patients and those with lower health literacy were less likely to stick with telemonitoring technology. Despite this, patients who initiated the system showed high participation rates, with over half continuing to participate three days a week.
A Canadian study found that 12% of heart failure patients had moderate to severe vertebral compression fractures, a sign of osteoporosis. Only 15% of these patients were being treated for osteoporosis, despite having a higher risk for fractures.
Researchers analyzed data from studies on atrial fibrillation, finding that AFib significantly increases the risk for stroke, heart failure, and death. The studies suggest that AFib has a substantial economic impact on the US healthcare system, warranting further investigation to understand its true costs.
Research finds that women with heart failure who suppress their emotions tend to have higher symptoms of depression and anxiety, even with knowledge about their illness. This suggests that clinicians should consider individual coping styles when educating patients about their condition.
Research suggests that a balanced diet with mono- and polyunsaturated fats can improve cardiac function in patients with heart failure. By providing sufficient energy to the heart, a damaged heart can maintain its normal metabolic profile and utilize its preferred energy source.
A study found nearly one in five patients with heart failure have low health literacy, which is associated with a higher all-cause risk of death. Patients with low health literacy were more likely to have coexisting illnesses and had a higher risk of mortality after adjusting for demographic variables.
A study found that tai chi significantly improved mood and exercise self-efficacy in chronic heart failure patients without affecting physical differences. Researchers suggest tai chi as a safe alternative to conventional exercise training for improving daily life.
Patients with chronic heart failure who practiced tai chi had improved quality of life and increased exercise self-efficacy compared to those in an education group. The study also found no significant differences in physical fitness between the two groups.
A study found that HIV infection is associated with an increased risk of heart failure, even after adjusting for traditional risk factors. Patients with high baseline HIV-1 RNA levels also showed a higher risk of heart failure.
Cardiac specialists will use new guidelines to determine who should receive a mechanical heart-pumping device. The guidelines have the potential to change clinical practice patterns for patients with severe heart failure. Dr. Morgan's presentation at the ISHLT annual meeting in San Diego highlights the importance of these changes.
Researchers found that death rates within 30 days of initial hospitalization dropped by half, and one-year mortality fell by 20.6%, among U.S. veterans age 80 or older hospitalized for heart failure from 1999 to 2008. Improved outcomes were seen in the 90+ age group, where 30-day and one-year death rates decreased by 11% and 26%, respe...